By binding to VEGFR-2, ramucirumab blocks the binding of VEGF ligands, thereby inhibiting the activation of downstream signaling pathways responsible for endothelial cell proliferation and migration, essential processes for angiogenesis and tumor growth [108,109]. This evidence concerns the gene VEGFA and neoplasm.